3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
2
Sponsor Class
OTHER
2
OTHER_GOV
1
NIH
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
67
Breast
56
Genitourinary
31
Gastrointestinal
21
Thoracic
18
Sarcoma
14
Tumor-Agnostic
11
Head & Neck
10
CNS
10
Other solid neoplasm
7
Lymphoid
5
Dermatologic
4
Classical hematology
4
Plasma cell
2
Other hematologic neoplasm
2
NET
2
Endocrine
2
Myeloid
1
Conditions
Neuroendocrine Tumors
2
Sarcoma, Synovial
1
Recurrence
1
Pheochromocytoma
1
Paraganglioma
1
Osteosarcoma
1
Neuroblastoma
1
Meningioma
1
Medulloblastoma
1
Glioma
1
Glioblastoma
1
Esthesioneuroblastoma, Olfactory
1
Ependymoma
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
lutetium Lu 177 dotatate
32
Everolimus
19
Magnetic Resonance Spectroscopy
14
gallium Ga 68 dotatate
12
Temozolomide
12
Nivolumab
11
Capecitabine
10
pembrolizumab
9
lanreotide
9
cabozantinib
8
Positron Emission Tomography Computed Tomography
8
177Lu-octreotide, DOTA(0)-Tyr(3)-
8
Ga(III)-DOTATOC
7
3-Iodobenzylguanidine
7
Somatostatin
6
Octreotide
6
Lutetium-177
6
Carboplatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
telotristat ethyl
5
surufatinib
5
lenvatinib
5
Ipilimumab
5
Fluorodeoxyglucose F18
5
pasireotide
4
copper dotatate CU-64
4
avelumab
4
Single Photon Emission Computed Tomography Computed Tomography
4
Positron-Emission Tomography
4
Bevacizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
olaparib
×
NET
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled
NCT05870423
2025-06-05
PRRT-PARPi
Erasmus Medical Center
Phase 1
Recruiting
24 enrolled